Study Shows Promise for Pediatric Epilepsy Drug

CER-0001 is a formulation of tricaprilin, a medium-chain triglyceride designed to induce ketosis without the strict dietary limitations of a traditional ketogenic diet. The drug aims to provide an alternative energy source for the brain, which may help mitigate the metabolic deficits associated with certain neurological disorders. The U.S. Food and Drug Administration (FDA) has granted both Orphan Drug and Rare Pediatric Disease designations to tricaprilin for the treatment of infantile spasms. The Phase 1/2a open-label study enrolled eight infants with drug-resistant infantile epileptic spasms at clinical sites in Australia and Singapore. In the study, four of the eight participants (50%) saw a 50-75% reduction in seizure clusters, while two infants (25%) experienced a complete (100%) resolution of their spasms. The most frequently observed side effects were gastrointestinal, with 75% of the infants experiencing mild to moderate issues, including vomiting in 50% of participants. Two infants experienced severe adverse events; one was a case of bronchiolitis deemed unrelated to the treatment, and the other was an aspiration due to a feeding tube misplacement. Infantile spasms, also known as West Syndrome, is a rare and severe form of epilepsy that typically begins in the first year of life. The condition is often associated with poor long-term neurodevelopmental outcomes, and between 40% and 60% of patients do not respond to first-line therapies, creating a significant need for new treatment avenues. Following the promising pilot study results, Cerecin is planning a larger, randomized controlled trial to further confirm the drug's therapeutic potential. The company has received clearance from the FDA for an Investigational New Drug (IND) application, allowing it to proceed with the next phase of clinical development for CER-0001 in the United States.